当前位置:首页 - 行情中心 - 东亚药业(605177) - 财务分析 - 利润表

东亚药业

(605177)

  

流通市值:29.39亿  总市值:29.66亿
流通股本:1.14亿   总股本:1.15亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入466,139,228.82264,569,472.69940,185,710.07596,338,949.81
  营业收入466,139,228.82264,569,472.69940,185,710.07596,338,949.81
二、营业总成本531,028,171.96292,086,877.751,003,397,048.89657,126,527.92
  营业成本354,812,589.11208,142,084.78718,115,167.38441,536,593.35
  税金及附加8,923,385.215,037,663.7211,981,453.8410,361,481.67
  销售费用8,882,838.333,129,858.4912,765,068.459,735,338.46
  管理费用97,559,225.246,107,570.25161,104,471.63123,049,098.01
  研发费用42,860,999.3720,820,014.5186,763,471.0666,233,932.09
  财务费用17,989,134.748,849,68612,667,416.536,210,084.34
  其中:利息费用18,216,619.669,125,998.9817,347,089.5410,207,428.55
  其中:利息收入1,994,433.681,051,944.544,672,590.593,546,018.58
三、其他经营收益
  加:投资收益2,166,9521,235,387.122,934,648.082,292,116.88
  资产处置收益89,140.3813,690.53-387,524.12-12,707.18
  资产减值损失(新)-71,298,798.49-12,118,295.34-44,115,906.92-34,746,495.37
  信用减值损失(新)3,585,723.6296,366.37154,066.452,611,427.45
  其他收益7,069,067.763,341,256.8120,018,841.6310,998,033.4
四、营业利润-123,276,857.89-34,748,999.57-84,607,213.7-79,645,202.93
  加:营业外收入252,785.1960,335.511,646,014.431,066,237.83
  减:营业外支出3,122,883.17586,655.975,611,948.252,824,023.4
五、利润总额-126,146,955.87-35,275,320.03-88,573,147.52-81,402,988.5
  减:所得税费用-7,770,013.13-73,662.02-6,140,998.39-8,957,131.41
六、净利润-118,376,942.74-35,201,658.01-82,432,149.13-72,445,857.09
(一)按经营持续性分类
  持续经营净利润-118,376,942.74-35,201,658.01-82,432,149.13-72,445,857.09
(二)按所有权归属分类
  归属于母公司股东的净利润-118,376,942.74-35,201,658.01-82,391,993.93-72,409,578.27
  少数股东损益---40,155.2-36,278.82
  扣除非经常损益后的净利润-123,533,901.08-38,636,500.22-94,514,505.66-81,984,651.67
七、每股收益
  (一)基本每股收益-1.03-0.31-0.72-0.63
  (二)稀释每股收益-0.71-0.19-0.48-0.49
九、综合收益总额-118,376,942.74-35,201,658.01-82,432,149.13-72,445,857.09
  归属于母公司股东的综合收益总额-118,376,942.74-35,201,658.01-82,391,993.93-72,409,578.27
  归属于少数股东的综合收益总额---40,155.2-36,278.82
公告日期2026-08-312026-04-302026-04-232025-10-31
审计意见(境内)标准无保留意见
TOP↑